British researchers used an adenoviral vector strategy to develop a vaccine that can strengthen T cells' response against the hepatitis C virus. The study, published in the journal Science Translational Medicine, found the vaccine to be safe. Researchers are working on a second-stage trial among people infected with the virus, and a U.S. trial is being planned to study whether the vaccine can protect people at risk of infection.

Full Story:
Medical News Today

Related Summaries